Obesity is a major global public health concern and there is a desperate need to identify new targets to treat obesity. By targeting the lesser investigated CART pathway and identifying the elusive CART receptor this could make a significant inroad to the understanding of the causes of appetite control and the development of obesity.
Identifying Unintentional Effects Of Medication Using Statistical Genetics Analyses Of Large-scale Genetic And Genomic Data
Funder
National Health and Medical Research Council
Funding Amount
$251,441.00
Summary
An increasing number of studies have highlighted unknown adverse effects of medication, for example, use of statins to lower cholesterol with increased risk of type 2 diabetes. The gold standard approach to confirm these effects is randomised control trials, which may not always be feasible or ethical, and are very expensive. This project aims to apply innovative statistical genetics approaches to (genetic and genomic) 'big-data' to predict unknown effects of commonly prescribed medications.
Tackling Heterogeneity In The Etiology Of Major Depressive Disorder
Funder
National Health and Medical Research Council
Funding Amount
$2,552,669.00
Summary
Professor Martin and his team will join an international effort to identify the first 50 genes that underlie depression. They aim to recruit 20,000 participants for this study and hope that the outcomes of their research will contribute not only to the development of better treatments for depression, but more targeted therapies for individuals affected.
Can Decision Analytic Modelling Promote Clinical Translation Of Personalised Medicine Markers For Oncology Drugs?
Funder
National Health and Medical Research Council
Funding Amount
$69,893.00
Summary
Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widel ....Personalised medicine is an approach that has great potential to improve healthcare. There has been limited success to date, however, in utilising proposed tests in the clinical. It is proposed that use of mathematical models early in the development of personalised medicine tests will allow early understanding of the value that the test will have for patients and society. Such insight will help build a strong case to undertake the research required before personalised medicine can be more widely used to improve treatment for cancer.Read moreRead less
Treatment Of Genetic Liver Disease By Homologous Recombination In Vivo, Coupled With A Pharmoco-genetic Strategy For Selective Expansion Of Genetically Repaired Hepatocytes
Funder
National Health and Medical Research Council
Funding Amount
$920,836.00
Summary
This project seeks to exploit recent advancements in our ability to precisely “edit” and correct mutations underlying human genetic diseases. To improve therapeutic efficiencies of the system, we will deliver the technology using highly efficient virus-based systems and apply a novel post-repair selection process to preferentially repopulate the liver with gene-repaired cells. Demonstration of the strategy in a humanised mouse model will provide important preclinical data for human applications.
PHARMACOGENETICS OF ANTIDEPRESSANT RESPONSE AND REMISSION: TOWARD GENOTYPE-GUIDED PRESCRIBING IN MAJOR DEPRESSIVE DISORDER
Funder
National Health and Medical Research Council
Funding Amount
$435,524.00
Summary
A “one-size fits all” approach to antidepressant pharmacotherapy in depression is suboptimal. Current technology and scientific data support the transition to a personalised approach to antidepressant pharmacotherapy. My research will (1) develop and test genetic based algorithms for their ability to predict antidepressant response and remission and (2) evaluate the clinical validity and utility of currently available algorithms in clinical practice.
Leveraging Record Linkage For Single-indication Medications To Boost Recruitment In Psychiatric And Pharmaco- Genetics
Funder
National Health and Medical Research Council
Funding Amount
$1,840,595.00
Summary
Genome-wide association studies (GWAS) have shown that psychiatric disorders are highly polygenic and that increasing the power of these analyses by increasing the number of participants does lead to the identification of new treatment targets and biomarkers. We seek funding to greatly boost the power of GWAS for Schizophrenia and Bipolar Disorder by using prescription records to recruit individuals who have been prescribed medications that are only used to treat these conditions.